Real-world treatment patterns and opioid use in chronic low back pain patients initiating duloxetine versus standard of care

Journal of Pain Research

Volumn 6, Issue , 2013, Pages 825-835

  Andrews, Jeffrey Scott ^a   Wu, Ning ^b   Chen, Shih Yin ^b   Yu, Xia ^b   Peng, Xiaomei ^a   Novick, Diego ^a  

^a ELI LILLY AND COMPANY   (United States)

^b EVIDERA   (United States)

Author keywords

Duloxetine; Low back pain; Medications; Opioid

Indexed keywords

DULOXETINE; GABAPENTIN; MUSCLE RELAXANT AGENT; NARCOTIC ANALGESIC AGENT; PREGABALIN; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT ASSESSMENT; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT DURATION;

EID: 84888626630     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S50323     Document Type: Article

References (51)

1. Krismer M, van Tulder M. Low Back Pain Group of the B, Joint Health Strategies for Europe Project. Strategies for prevention and management of musculoskeletal conditions. Low back pain (non-specific). Best Pract Res Clin Rheumatol. 2007;21(1):77-91.
2. Loney PL, Stratford PW. The prevalence of low back pain in adults: a methodological review of the literature. Phys Ther. 1999;79(4): 384-396.
3. Hart LG, Deyo RA, Cherkin DC. Physician office visits for low back pain. Frequency, clinical evaluation, and treatment patterns from a US national survey. Spine (Phila PA 1976). 1995;20(1):11-19.
4. van Tulder M, Koes B, Bombardier C. Low back pain. Best Pract Res Clin Rheumatol. 2002;16(5):761-775.
5. US Department of Health and Human Services. Healthy People 2020. Arthritis, osteoporosis, and chronic back conditions [webpage on the internet]. Available from: http://healthypeople.gov/2020/topicsobjectives2020/overview.aspx?topicid=3. Accessed June 15, 2013.
6. Katz JN. Lumbar disc disorders and low-back pain: socioeconomic factors and consequences. J Bone Joint Surg Am. 2006;88 Suppl 2: 21-24.
7. Dagenais S, Caro J, Haldeman S. A systematic review of low back pain cost of illness studies in the United States and internationally. Spine J. 2008;8(1):8-20.
8. Kuijer W, Brouwer S, Preuper HR, Groothoff JW, Geertzen JH, Dijkstra PU. Work status and chronic low back pain: exploring the International Classification of Functioning, Disability and Health. Disabil Rehabil. 2006;28(6):379-388.
9. Wilson JF. In the clinic. Low back pain. Ann Int Med. 2008;148(9): ITC5-1-ITC5-16.
10. Miller SM. Low back pain: pharmacologic management. Prim Care. 2012;39(3):499-510.
11. Chou R, Qaseem A, Snow V, et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Int Med. 2007;147(7): 478-491.
12. Hestbaek L, Leboeuf-Yde C, Manniche C. Low back pain: what is the long-term course? A review of studies of general patient populations. Eur Spine J. 2003;12(2):149-165.
13. Goertz M, Thorson D, Bonsell J, Bonte B, Campbell R, Haake B, Johnson K, Kramer C, Mueller B, Peterson S, Setterlund L, Timming R. Adult acute and subacute low back pain. Institute for Clinical Systems Improvement (ICSI); 2012 Nov. Available from: https://www.icsi.org/_asset/bjvqrj/LBP.pdf. Accessed June 15, 2013.
14. Pengel LH, Herbert RD, Maher CG, Refshauge KM. Acute low back pain: systematic review of its prognosis. BMJ. 2003;327(7410):323.
15. Last AR, Hulbert K. Chronic low back pain: evaluation and management. Am Fam Physician. 2009;79(12):1067-1074.
16. Nourjah P, Ahmad SR, Karwoski C, Willy M. Estimates of acetaminophen (Paracetomal)-associated overdoses in the United States. Pharmacoepidemiol Drug Saf. 2006;15(6):398-405.
17. van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM. Muscle relaxants for non-specific low back pain. Cochrane Database Syst Rev. 2003;(2):CD004252.
18. Chou R, Huffman LH. American Pain Society; American College of Physicians. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Int Med. 2007;147(7):505-514.
19. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol depend. 2006;81(2):103-107.
20. Lee TJ. Pharmacologic treatment for low back pain: one component of pain care. Phys Med Rehabil Clin N Am. 2010;21(4):793-800.
21. Deyo RA, Mirza SK, Turner JA, Martin BI. Overtreating chronic back pain: time to back off? J Am Board Fam Med. 2009;22(1):62-68.
22. Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf. 2006;15(9): 618-627.
23. Mitchell JM. Utilization trends for advanced imaging procedures: evidence from individuals with private insurance coverage in California. Med Care. 2008;46(5):460-466.
24. Martin BI, Deyo RA, Mirza SK, et al. Expenditures and health status among adults with back and neck problems. JAMA. 2008;299(6): 656-664.
25. Cymbalta® (duloxetine delayed-release capsules) [package insert]. Indianapolis, IN: Lilly USA, LLC; 2010 [webpage on the internet] Available from: http://pi.lilly.com/us/cymbalta-pi.pdf. Accessed July 24, 2012.
26. Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RM. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther. 2004;311(2):576-584.
27. Skljarevski V, Zhang S, Desaiah D, et al. Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial. J Pain. 2010;11(12):1282-1290.
28. Skljarevski V, Zhang S, Chappell AS, Walker DJ, Murray I, Backonja M. Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded study. Pain Med. 2010;11(5):648-657.
29. Skljarevski V, Ossanna M, Liu-Seifert H, et al. A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol. 2009;16(9):1041-1048.
30. National Center for Health Statistics. Classification of Diseases and Injuries. Center for Disease Control. Available from: ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD-9/ucod.txt. Accessed April 18, 2012.
31. Argoff CE, Silvershein DI. A comparison of long-and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. Mayo Clin Proc. 2009;84(7):602-612.
32. Upshur CC, Luckmann RS, Savageau JA. Primary care provider concerns about management of chronic pain in community clinic populations. J Gen Intern Med. 2006;21(6):652-655.
33. Chen S, Wu N, Fraser K, Boulanger L, Zhao Y. Opioid use and healthcare costs among patients with DPNP initiating duloxetine versus other treatments. Curr Med Res Opin. 2010;26(10):2507-2516.
34. Zhao Y, Wu N, Chen S, Boulanger L, Police RL, Fraser K. Changes in opioid use and healthcare costs among US patients with diabetic peripheral neuropathic pain treated with duloxetine compared with other therapies. Curr Med Res Opin. 2010;26(9):2147-2156.
35. Freynhagen R, Baron R. The evaluation of neuropathic components in low back pain. Curr Pain Headache Rep. 2009;13(3):185-190.
36. Deyo RA, Weinstein JN. Low back pain. N Engl J Med. 2001;344(5): 363-370.
37. Robinson MJ, Edwards SE, Iyengar S, Bymaster F, Clark M, Katon W. Depression and pain. Front Biosci (Landmark Ed). 2009;14: 5031-5051.
38. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6(5):346-356.
39. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67(8):1411-1420.
40. Arnold LM. Duloxetine and other antidepressants in the treatment of patients with fibromyalgia. Pain Med. 2007;8 Suppl 2:S63-S74.
41. Arnold LM, Pritchett YL, D'Souza DN, Kajdasz DK, Iyengar S, Wernicke JF. Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebo-controlled clinical trials. J Womens Health (Larchmt). 2007;16(8):1145-1156.
42. Chappell AS, Ossanna MJ, Liu-Seifert H, et al. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial. Pain. 2009;146(3):253-260.
43. Lai KC, Chu KM, Hui WM, et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med. 2005;118(11):1271-1278.
44. Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305(13):1315-1321.
45. Boulanger L, Wu N, Chen SY, et al. Predictors of pain medication selection among patients diagnosed with fibromyalgia. Pain Pract. 2012;12(4):266-275.
46. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112(3):372-380.
47. Katz WA, Barkin RL. Dilemmas in chronic/persistent pain management. Dis Mon. 2010;56(4):233-250.
48. Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115(12): 1634-1642.
49. Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006;99(3):132-140.
50. Staiger TO, Gaster B, Sullivan MD, Deyo RA. Systematic review of antidepressants in the treatment of chronic low back pain. Spine. 2003;28(22):2540-2545.
51. Brunton S, Wang F, Edwards SB, et al. Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies. Drug Saf. 2010;33(5):393-407.